Butylphthalide Improves Neurological Function in Acute Cerebral Infarction Patients via Netrin/DCC/VEGF Signaling Pathway

Wenyuan Cao

Background and Objective: Ischemia in acute cerebral infarction leads to brain tissue damage. Butylphthalide improves blood flow, reduces edema and protects mitochondria, benefiting patient prognosis, but its precise mechanism requires further study. This study aimed to evaluate the role of Netrin/DCC/VEGF signaling pathway in the prognosis of patients with acute cerebral infarction and treated with butylphthalide. Materials and Methods: The 131 patients with acute cerebral infarction from July, 2019 to February, 2021 were selected and grouped according to the randomized control principle. The control group (CG) (65 cases) received administration of atorvastatin calcium while the experimental group (EG) (66 cases) was treated with atorvastatin calcium+butylphthalide. The cerebral perfusion indexes, serum indexes, neurological function, daily life activities and self-care capacity, Netrin/DCC/VEGF signaling pathway-related protein and prognosis of 2 groups were compared. Results: After treatment in the EG, CVR, bilateral peak systolic velocity and mean blood flow velocity, serum BDNF, 3-MST, fibulin-5 levels and Netrin-1, DCC and VEGF protein expression levels were significantly higher than those in the CG, while PI, ICAM-1, GFAP, β-actin, S100β, HMGB1 and PTX3 levels were significantly lower than those in the CG (p<0.05). Conclusion: Butylphthalide can regulate cerebral blood perfusion, reduce neuronal damage, reduce inflammatory cascade, repair cerebrovascular damage, enhance the ability of daily living and improve prognosis in patients with acute cerebral infarction.

View Fulltext Back